Premium
Effects of Chronic Striatal Kainate Lesions on Some Dopaminergic Parameters and Enkephalin Immunoreactive Neurons in the Basal Ganglia
Author(s) -
Schwarcz Robert,
Fuxe Kjell,
Hökfelt Tomas,
Terenius Lars,
Goldstein Menek
Publication year - 1980
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1980.tb09646.x
Subject(s) - enkephalin , tyrosine hydroxylase , substantia nigra , medicine , dopamine , endocrinology , choline acetyltransferase , striatum , basal ganglia , axon , dopaminergic , chemistry , biology , neuroscience , cholinergic , receptor , central nervous system , opioid
The chronic effects of kainate‐induced lesions of the neostriatum have been evaluated in rats 12 months following the injection of kainic acid. Light microscopical analysis revealed marked disappearance of nerve cells in the neostriatum, with some cells remaining within the medial and lateral zone of the neostriatum and in the most ventral part. The rest of the markedly atrophied neostriatum was mainly made up of densely packed myelinated nerve bundles. Tyrosine hydroxylase immunoreactivity was used as a marker for dopamine neurons and revealed that tyrosine hydroxylase immunoreactive nerve terminals remained between the axon bundles in the striatum and that tyrosine hydroxylase immunoreactive nerve cell bodies in the substantia nigra seemed intact. Studies on enkephalin immunoreactive neurons revealed a marked disappearance of such nerve cells and nerve terminals within the neostriatum. Neurochemical analysis showed a clearcut reduction in the number of dopamine receptors as evaluated by studies on both [ 3 H]spiperone binding and on [ 3 H]ADTN binding. Dopamine levels remained unchanged while choline acetyltransferase activity was reduced significantly. Taken together, the present findings demonstrate that the chronically kainate lesioned striatum is characterized by a substantial loss of enkephalin immunoreactive and cholinergic nerve cells and a marked reduction in the number of dopamine receptors. These findings are discussed in relation to neurochemical and therapeutic aspects of Huntington's disease.